93 related articles for article (PubMed ID: 19252468)
1. [Molecular markers of carcinogenesis in the diagnostics of cervical cancer].
Bedkowska GE; Ławicki S; Szmitkowski M
Postepy Hig Med Dosw (Online); 2009 Feb; 63():99-105. PubMed ID: 19252468
[TBL] [Abstract][Full Text] [Related]
2. [New tumour markers useful in diagnostics and monitoring of cervical cancer].
Bedkowska GE; Lawicki S; Szmitkowski M
Przegl Lek; 2007; 64(12):1022-7. PubMed ID: 18595508
[TBL] [Abstract][Full Text] [Related]
3. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers.
Sidorkiewicz I; Zbucka-Krętowska M; Zaręba K; Lubowicka E; Zajkowska M; Szmitkowski M; Gacuta E; Ławicki S
BMC Cancer; 2019 Apr; 19(1):398. PubMed ID: 31035945
[TBL] [Abstract][Full Text] [Related]
5. [Tumor markers useful in the diagnostics and monitoring of endometrial and cervical cancer].
Bedkowska GE; Lawicki S; Szmitkowski M
Postepy Hig Med Dosw (Online); 2007; 61():122-8. PubMed ID: 17369780
[TBL] [Abstract][Full Text] [Related]
6. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
7. Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.
Gaarenstroom KN; Bonfrer JM; Korse CM; Kenter GG; Kenemans P
Anticancer Res; 1997; 17(4B):2955-8. PubMed ID: 9329574
[TBL] [Abstract][Full Text] [Related]
8. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract][Full Text] [Related]
9. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
Kulpa J; Wójcik E; Radkowski A; Kolodziejski L; Stasik Z
Anticancer Res; 2000; 20(6D):5035-40. PubMed ID: 11326663
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor.
Kaminska J; Kowalska M; Kotowicz B; Fuksiewicz M; Glogowski M; Wojcik E; Chechlinska M; Steffen J
Oncology; 2006; 70(2):115-25. PubMed ID: 16645324
[TBL] [Abstract][Full Text] [Related]
11. [Tumor makrers in cervical cancer].
Markowska J
Ginekol Pol; 2007 Sep; 78(9):715-8. PubMed ID: 18159826
[TBL] [Abstract][Full Text] [Related]
12. [Tumor markers in uterine cancers].
Fukasawa I; Kousaka N; Kun Z; Inaba N
Gan To Kagaku Ryoho; 2002 Feb; 29(2):333-40. PubMed ID: 11865645
[TBL] [Abstract][Full Text] [Related]
13. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, and squamous cell carcinoma antigen in the detection of cervical cancers.
Lam CP; Yuan CC; Jeng FS; Tsai LC; Yeh SH; Ng HT
Zhonghua Yi Xue Za Zhi (Taipei); 1992 Jul; 50(1):7-13. PubMed ID: 1326391
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-Colony stimulating factor and macrophage-colony stimulating factor in patients with non-small-cell lung cancer.
Mroczko B; Szmitkowski M; Niklinski J
Clin Chem Lab Med; 2001 May; 39(5):374-9. PubMed ID: 11434384
[TBL] [Abstract][Full Text] [Related]
16. [The plasma levels and diagnostic utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients].
Lawicki S; Bedkowska E; Gacuta-Szumarska E; Knapp P; Szmitkowski M
Pol Merkur Lekarski; 2008 Jul; 25(145):38-42. PubMed ID: 18839612
[TBL] [Abstract][Full Text] [Related]
17. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment serum CYFRA 21-1 level correlates significantly with survival of cervical cancer patients: a multivariate analysis of 506 cases.
Piao X; Kong TW; Chang SJ; Paek J; Chun M; Ryu HS
Gynecol Oncol; 2015 Jul; 138(1):89-93. PubMed ID: 25913134
[TBL] [Abstract][Full Text] [Related]
19. CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus.
Nakamura T; Ide H; Eguchi R; Hayashi K; Takasaki K; Watanabe S
Dis Esophagus; 1998 Jan; 11(1):35-9. PubMed ID: 9595230
[TBL] [Abstract][Full Text] [Related]
20. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
